INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Edgewise Therapeutics and its officers or directors [1] Group 1: Company Performance - On June 26, 2025, Edgewise reported clinical trial data for its lead asset, sevasemten, targeting Becker and Duchenne muscular dystrophies, which it described as "positive" [3] - Despite the positive characterization, the U.S. FDA indicated that the CANYON data was insufficient for accelerated approval during a Type C meeting [3] - Following this announcement, Edgewise's stock price decreased by $1.27 per share, or 8.86%, closing at $14.33 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Edgewise regarding claims of potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]